Drug Profile


Alternative Names: PCT-233; PUR-0110; Thykamine™

Latest Information Update: 22 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PurGenesis Technologies
  • Developer Devonian
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Antioxidants; Cytokine inhibitors; Interleukin 10 modulators; Reactive oxygen species inhibitors; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Ulcerative colitis
  • Preclinical Cardiovascular disorders
  • No development reported Psoriasis

Most Recent Events

  • 09 Nov 2017 Phase-II clinical trials in Atopic dermatitis in Canada (Topical)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Psoriasis in Canada (Topical, Cream)
  • 04 Jul 2017 Updated pharmacodynamics, efficacy and safety data from a phase IIa trial in Ulcerative colitis reported by Devonian (3255712; 3254897)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top